Wafik S. El-Deiry: Helping advance precision oncology research at WIN Consortium in Cancer Personalized Medicine
Wafik S. El-Deiry shared a post on LinkedIn:
“Honored and grateful for the opportunity to work with Dr. Razelle Kurzrock at the non-profit WIN Consortium in cancer personalized medicine to help advance precision oncology research.
WIN has been a leader in use of transcriptomics and AI algorithms since its founding by the late Drs. John Mendelsohn at MD Anderson Cancer Center and Thomas Tursz at Gustave Roussy. WIN’s ethos as a community of like-minded individuals across the world is to innovate, to collaborate (not compete) and to have global impact. The Founders believed and we believe today that we can do more working together through collaboration.
For the field of Precision Oncology, we are working on the next generation of best-in-class precision oncology clinical trials, the signature WIN Symposia, and an international WIN Molecular Tumor Board. We care about access and equity in medicine and oncology.
We are growing, forming strategic collaborations, as we address the challenges of precision oncology.
We believe patients with cancer will be treated in a much more personalized way in the future to address tumor heterogeneity and evolution as well as host and environmental factors to achieve better outcomes and more cures.
At the molecular and cellular levels, cancer is incredibly complex and so it is important not only to continue to unravel its nature and vulnerabilities but to take a wholistic approach to target its many characteristics. There is hope for precision prevention as well.
Precision Oncology offers a way to address cancer’s many challenges building on two+ decades of progress in cancer biology research, N-of-1 basket trials, AI technologies, omics, targeted and immunotherapeutics.”
Source: Wafik S. El-Deiry/LinkedIn
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023